1. Who This Guide Is For This guide is written for IP counsel, portfolio managers, R&D leads, and institutional investors […]
AI Drug Patents: The Complete IP Strategy Guide for Pharma and Biotech Read Post »
Executive Summary The global biopharmaceutical sector has entered a decisive inflection point in early 2026, characterized by the convergence of
What Patent Timing Actually Decides A pharmaceutical patent filed on Day 1 of discovery and a patent filed after Phase
The Power of Patience: The Pharma Playbook for Extending Market Exclusivity Read Post »
Atorvastatin lost its primary patent on November 30, 2011. What followed was the most studied loss-of-exclusivity response in pharmaceutical history.
1. Why Patent Portfolio Management Determines Market Survival Pharmaceutical patent portfolio management is not a legal overhead function. It is
Drug Patent Portfolio Management: The Definitive Playbook for Pharma IP Teams Read Post »
Why China’s Patent System Demands Your Full Attention Now China filed more than 1.5 million patent applications in 2022, making
Executive Summary and Key Findings The USPTO’s Drug Patent and Exclusivity Study, produced in collaboration with the FDA at the
1. What the 505(b)(2) Pathway Actually Is (and What It Isn’t) The 505(b)(2) New Drug Application (NDA) is a hybrid
505(b)(2) Mastery: The Complete IP Strategy Guide for Drug Lifecycle Extension Read Post »
A technical deep dive for pharma IP teams, portfolio managers, R&D leads, and institutional investors Why Most Generic Drug Strategies
Sign in or create a free account to read this DrugPatentWatch article
